Join The Alzheimer’s Test Priority List

 

Recently awarded by the FDA Breakthrough Device Designation for the detection of synuclein, a biomarker affecting 40% of Alzheimer’s patients, Amprion is on the fast-track of securing both the FDA and CLIA approvals for the commercial rollout of the Synuclein Test, using spinal tap and/or blood.

We anticipate the launch of the Synuclein Test by first half of 2021. Sign up to stay ahead of the curve on our breakthrough early testing for Alzheimer’s!


    I'm a DoctorI'm a Neurologistother, please specify